Summary

Neurodegeneration refers to the progressive loss of neuron structure or function, which may eventually lead to cell death. Many neurodegenerative diseases, such as amyotrophic lateral sclerosis, multiple sclerosis, Parkinson's disease, Alzheimer's disease, Huntington's disease and prion disease, are the results of neurodegenerative processes. Neurodegeneration can be found in many different levels of neuronal circuits in the brain, from molecules to systems. Since there is no known method to reverse the progressive degeneration of neurons, these diseases are considered incurable. Biomedical research has revealed many similarities between these diseases at the subcellular level, including atypical protein assembly (such as protein diseases) and induction of cell death. These similarities indicate that progress in the treatment of one neurodegenerative disease may also improve other diseases. This collection of entries aims to collect various medical research results related to neurodegeneration. We invite researchers to share their new results and ideas related to neurodegeneration.

Expand All
Entries
Topic Review
Nrf2 Activation in Neurodegenerative Diseases
Neurodegenerative diseases are incurable and debilitating conditions that result in progressive degeneration and loss of nerve cells. Oxidative stress has been proposed as one factor that plays a potential role in the pathogenesis of neurodegenerative disorders since neuron cells are particularly vulnerable to oxidative damage. Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) is strictly related to anti-inflammatory and antioxidative cell response; therefore, its activation and the consequent enhancement of the related cellular pathways have been proposed as a potential therapeutic approach.
  • 531
  • 12 Apr 2023
Topic Review
MicroRNA-502-3p and Human Diseases: Focus on Alzheimer's Disease
The microRNA-500’s family has five different genotypes: microRNA-362, microRNA-500a, microRNA-500b, microRNA-501, and microRNA-502 (Genesnames.org). All the forms of miR-500 family members are expressed in humans and different animal species. The miR-502-3p sequence is 22 nucleotides long and is found in Homo sapiens (Has-miR-502-3p) as annotated by 7 gene databases such as MalaCards, miRBase, GeneCards, TarBase, ENA, RefSeq, and LncBase. The miR-502 were also found to be conserved in seven different animal species such as Cow (Bos taurus) Bta-miR-502a; Dog (Canis lupus familiaris) Cfa-miR-502; Horse (Equus caballus) Eca-miR-502-3p; Gorilla (Gorilla gorilla) Ggo-miR-502a; Rhesus monkey (Macaca mulatta) Mml-miR-502-3p); Rabbit (Oryctolagus cuniculus) Ocu-miR-502-3p; and Bornean orangutan (Pongo pygmaeus) Ppy-miR-502-3p (https://rnacentral.org/rna) (accessed on 26 February 2023). The miR-502-3p is encoded by the MIR502 gene (ENSG00000272080) which is composed of an 86 base-pairs genomic sequence, a plus stranded RNA orientation starting from 50,014,598, and ending at 50,014,683. The MiR502 gene is located at the Chromosome X genomic location: 50,014,598-50,014,683 forward strands.
  • 411
  • 13 Apr 2023
Topic Review
Microglia and Astrocytes Dysfunction in Parkinson’s Disease
Parkinson’s disease (PD) is the second most common neurodegenerative disease, with symptoms such as tremor, bradykinesia with rigidity, and depression appearing in the late stage of life. The key hallmark of PD is the loss or death of dopaminergic neurons in the region substantia nigra pars compacta. Neuroinflammation plays a key role in the etiology of PD, and the contribution of immunity-related events spurred the researchers to identify anti-inflammatory agents for the treatment of PD. Microglia and astrocyte dysregulation has been reported in PD. Patients with PD develop neural toxicity, inflammation, and inclusion bodies due to activated microglia and a-synuclein–induced astrocyte conversion into A1 astrocytes. 
  • 456
  • 13 Apr 2023
Topic Review
Application of Proteomics in Optic Nerve Injury Diseases
Optic nerve damage is a common cause of blindness. Optic nerve injury is often accompanied by fundus vascular disease, retinal ganglion cell apoptosis, and changes in retinal thickness. These changes can cause alterations in protein expression within neurons in the retina. Proteomics analysis offers conclusive evidence to decode a biological system. Optic nerve damage can significantly reduce the vision of patients, thereby having a serious impact on their daily lives and their families. In clinical practice, optic nerve injury is mainly diagnosed by optical tomography (OCT) detection and by fundus angiography. 
  • 274
  • 12 Apr 2023
Topic Review
Demyelination and Remyelination Strategies for Multiple Sclerosis
All licensed medications for multiple sclerosis (MS) target the immune system. Albeit promising preclinical results demonstrated disease amelioration and remyelination enhancement via modulating oligodendrocyte lineage cells, most drug candidates showed only modest or no effects in human clinical trials. This might be due to the fact that remyelination is a sophistically orchestrated process that calls for the interplay between oligodendrocyte lineage cells, neurons, central nervous system (CNS) resident innate immune cells, and peripheral immune infiltrates and that this process may somewhat differ in humans and rodent models used in research. 
  • 512
  • 11 Apr 2023
Topic Review
The Sigma-2 Receptor
The sigma-2 receptor (S2R), encoded by TMEM97, is expressed in brain and retinal cells, and regulates cell functions via its co-receptor progesterone receptor membrane component 1 (PGRMC1), and through other protein–protein interactions. S2R modulates key pathways, including autophagy, trafficking, oxidative stress, and amyloid-β and α-synuclein toxicity, involved in age-related degenerative diseases of the central nervous system. Furthermore, S2R modulation can ameliorate functional deficits in cell-based and animal models of neurodegenerative disease.
  • 546
  • 06 Apr 2023
Topic Review
Vascular Alterations in Alzheimer’s Disease Brains
Alzheimer’s disease (AD) is the most common degenerative disorder in the elderly in developed countries. Growing evidence is pointing at endothelial dysfunction as a key player in the cognitive decline course of AD. As a main component of the blood–brain barrier (BBB), the dysfunction of endothelial cells driven by vascular risk factors associated with AD allows the passage of toxic substances to the cerebral parenchyma, producing chronic hypoperfusion that eventually causes an inflammatory and neurotoxic response.
  • 315
  • 06 Apr 2023
Topic Review
Immunization with Neural-Derived Peptides in Neurodegenerative Diseases
Neurodegenerative diseases (NDDs) are a major health problem worldwide. Statistics suggest that in America in 2030 there will be more than 12 million people suffering from a neurodegenerative pathology. Furthermore, the increase in life expectancy enhances the importance of finding new and better therapies for these pathologies. NDDs could be classified into chronic or acute, depending on the time required for the development of clinical symptoms and brain degeneration. Nevertheless, both chronic and acute stages share a common immune and inflammatory pathway in their pathophysiology. Immunization with neural-derived peptides (INDP) is a novel therapy that has been studied during the last decade. By inoculating neural-derived peptides obtained from the central nervous system (CNS), this therapy aims to boost protective autoimmunity, an autoreactive response that leads to a protective phenotype that produces a healing environment and neuroregeneration instead of causing damage. 
  • 296
  • 03 Apr 2023
Topic Review
Group-I-mGluRs and Microglia in CNS: Focus on ALS
Microglia cells are the resident immune cells of the central nervous system. They act as the first-line immune guardians of nervous tissue and central drivers of neuroinflammation. Any homeostatic alteration that can compromise neuron and tissue integrity could activate microglia. 
  • 274
  • 03 Apr 2023
Topic Review
α-Synuclein Aggregation in Treatment of Parkinson’s Disease
Parkinson’s disease, the second most common neurodegenerative disorder worldwide, is characterized by the accumulation of protein deposits in the dopaminergic neurons. These deposits are primarily composed of aggregated forms of α-Synuclein (α-Syn). PD is a complex pathology initially associated with motor deficiencies, as a result of an acute neuronal loss in substantia nigra pars compacta (SNc), with a significant dopaminergic (DA) impairment.
  • 922
  • 31 Mar 2023
  • Page
  • of
  • 49
>>